Glooko And T1D Exchange Enter Partnership To Leverage Device Data From Type 1 Diabetics
T1D Exchange, a nonprofit research group, will use Glooko’s diabetes data management platform to leverage diabetes device data from thousands of type 1 diabetics and link it with patients’ health records data at participating medical centers. Thanks to the agreement, researchers will gain access to data that can be used to improve patient care and outcomes.
You may also be interested in...
In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.
ADA 2019: Real-World Study Shows Abbott's FreeStyle Libre CGM Reduced HbA1c Levels In Type 2 Diabetics
At this year's annual American Diabetes Association (ADA) conference, Abbott presented real-world data from its FreeStyle Libre CGM suggesting it reduces HbA1c in type 2 diabetics. Look for more ADA coverage this week.
Glooko entered a partnership to integrate Companion Medical's InPen insulin data into Glooko's diabetes management systems.